Romidepsin accelerated the number of FOXP3+ regulatory T cells, reduced the number of IFN-γ+ CD8+ T cells, and alleviated Th1/Th2 ratio in TME in subcutaneous model and colitis-related cancer mice. The gene discussed is CD8A; the disease is cancer.